JP2005527470A5 - - Google Patents

Download PDF

Info

Publication number
JP2005527470A5
JP2005527470A5 JP2003524606A JP2003524606A JP2005527470A5 JP 2005527470 A5 JP2005527470 A5 JP 2005527470A5 JP 2003524606 A JP2003524606 A JP 2003524606A JP 2003524606 A JP2003524606 A JP 2003524606A JP 2005527470 A5 JP2005527470 A5 JP 2005527470A5
Authority
JP
Japan
Prior art keywords
composition
nesp
methionine
concentration
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003524606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527470A (ja
JP4493334B2 (ja
Filing date
Publication date
Priority claimed from US09/945,517 external-priority patent/US20030104996A1/en
Application filed filed Critical
Publication of JP2005527470A publication Critical patent/JP2005527470A/ja
Publication of JP2005527470A5 publication Critical patent/JP2005527470A5/ja
Application granted granted Critical
Publication of JP4493334B2 publication Critical patent/JP4493334B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003524606A 2001-08-30 2002-08-29 Hsa非含有組成物中のnesp/epoの安定化剤としてのl−メチオニン Expired - Lifetime JP4493334B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/945,517 US20030104996A1 (en) 2001-08-30 2001-08-30 L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
PCT/US2002/027855 WO2003020299A1 (en) 2001-08-30 2002-08-29 L-methionine as a stabilizer for nesp/epo in hsa-free formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010052203A Division JP2010138195A (ja) 2001-08-30 2010-03-09 Hsa非含有組成物中のnesp/epoの安定化剤としてのl−メチオニン

Publications (3)

Publication Number Publication Date
JP2005527470A JP2005527470A (ja) 2005-09-15
JP2005527470A5 true JP2005527470A5 (https=) 2006-10-05
JP4493334B2 JP4493334B2 (ja) 2010-06-30

Family

ID=25483206

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003524606A Expired - Lifetime JP4493334B2 (ja) 2001-08-30 2002-08-29 Hsa非含有組成物中のnesp/epoの安定化剤としてのl−メチオニン
JP2010052203A Pending JP2010138195A (ja) 2001-08-30 2010-03-09 Hsa非含有組成物中のnesp/epoの安定化剤としてのl−メチオニン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010052203A Pending JP2010138195A (ja) 2001-08-30 2010-03-09 Hsa非含有組成物中のnesp/epoの安定化剤としてのl−メチオニン

Country Status (10)

Country Link
US (1) US20030104996A1 (https=)
EP (1) EP1439848B1 (https=)
JP (2) JP4493334B2 (https=)
KR (1) KR100596610B1 (https=)
CN (1) CN100384468C (https=)
CA (1) CA2458386C (https=)
MX (1) MXPA04001774A (https=)
PL (1) PL374122A1 (https=)
TW (1) TWI327068B (https=)
WO (1) WO2003020299A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219131B1 (pl) * 2000-05-15 2015-03-31 Hoffmann La Roche Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
AU2006295340B2 (en) * 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
EP2170268A2 (en) * 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009009406A1 (en) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
EP2249801A2 (en) * 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
CN117530912A (zh) 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
BRPI0918978A2 (pt) * 2008-09-10 2015-12-01 Genentech Inc composições e métodos a prevenção da degradação oxidativa das proteínas
CA2765220A1 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
FR2954325B1 (fr) 2009-12-23 2012-02-03 Flamel Tech Sa Polymere amphiphile fonctionnalise par la methionine
US20110150837A1 (en) * 2009-12-23 2011-06-23 Flamel Technologies Amphiphilic polymer functionalized by methionine
MX2012007676A (es) * 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
CN107412737A (zh) 2010-01-19 2017-12-01 韩美科学株式会社 长效g‑csf缀合物的液体制剂
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
DK2603232T3 (da) 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc Stabile formuleringer af linaclotid
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
SG10201707477SA (en) * 2013-03-13 2017-10-30 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
JP6541581B2 (ja) 2013-03-15 2019-07-10 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited 低濃度抗体製剤
EP3094735A1 (en) * 2014-01-13 2016-11-23 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
RU2599031C1 (ru) * 2015-08-11 2016-10-10 Общество с ограниченной ответственностью "АйВиФарма" Водная композиция рекомбинантного фолликулостимулирующего гормона человека (варианты)
EP3397243A1 (en) * 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Use of tryptophan derivatives for protein formulations
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
US11338018B2 (en) 2016-12-19 2022-05-24 Harrow Ip, Llc Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
WO2018142514A1 (ja) * 2017-02-01 2018-08-09 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
KR102655498B1 (ko) 2017-09-07 2024-04-11 제이씨알 파마 가부시키가이샤 수성 의약 조성물
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
BR112021004649A2 (pt) * 2018-09-13 2021-06-01 F. Hoffmann-La Roche Ag formulação farmacêutica e uso de uma formulação
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US20250032579A1 (en) * 2021-12-03 2025-01-30 Jecho Biopharmaceuticals Co., Ltd. Formulation, and preparation method therefor and use thereof
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
JPS6297229A (ja) * 1985-10-21 1987-05-06 Nec Kansai Ltd 螢光膜の形成方法
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001030320A1 (en) * 1999-10-22 2001-05-03 Amgen Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
PL219131B1 (pl) * 2000-05-15 2015-03-31 Hoffmann La Roche Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations

Similar Documents

Publication Publication Date Title
JP2005527470A5 (https=)
CA2458386A1 (en) L-methionine as a stabilizer for nesp/epo in hsa-free formulations
RU2113845C1 (ru) Водный раствор интерферона
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
JP2005537234A5 (https=)
CA2275890A1 (en) Stable liquid interferon formulations
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
JP2003506416A5 (https=)
CY1115918T1 (el) Συνθεσεις βασιζομενες επι διακλαδισμενης αλυσου αμινοξεων για βελτιωση της μυοκαρδιακης κοιλιακης λειτουργιας σε ασθενεις που υποφερουν απο διαβητη
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
ATE460155T1 (de) Pharmazeutische zusammensetzung mit lyophilisiertem rekombinantem faktor viii ohne albumin als stabilisator
JPS6021570B2 (ja) ド−パ類の高濃度製剤の製法
CY1110106T1 (el) Φαρμακοτεχνικες μορφες για την παρατεταμενη απελευθερωση ιντερφερονων και θεραπευτικες εφαρμογες αυτων
IT1187828B (it) Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
JPS59181224A (ja) 安定なインタ−フエロン製剤の製法
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
BRPI0414157A (pt) polipeptìdeo isolado, ácido nucleico isolado, método para inibir a infecção por vìrus da sìndrome da mancha branca de um crustáceo, e, alimento para um crustáceo
JP2004534073A5 (https=)
DE69315388D1 (de) Aus bakteriellen Proteinen bestehender Extrakt, Verfahren zur dessen Herstellung und diesen Extrakt enthaltende pharmazeutische Zusammensetzung
KR950024769A (ko) 고농도 tcf 제제
KR890003409A (ko) 점막 투여시 흡수 촉진제로서의 시클릭 펩티드
JP2004538275A5 (https=)
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
RU2238758C2 (ru) Водный раствор интерферона-альфа-два человека для инъекций